Impact BiomedicalIBO
13F holders, Q1 2026 (March 31)20holders −4
4new positions
9sold out
$0.60avg. 13F price*
At the end of Q1 2026, 20 institutions reported holding Impact Biomedical Inc. (IBO) in their 13F filings, down 4 from Q4 2025. 4 opened new positions and 9 sold out. The largest holders were Geode Capital Management, LLC ($716K), Vanguard Capital Management LLC ($425K) and State Street Corp. ($365K).
- Company
- Impact Biomedical Inc.
- CUSIP
- 45259L205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1K |
| Exits | 9 | $104K |
All 13F filers, Q4 2025 → Q1 2026: 1,981,108 shares bought and 209,393 shares sold, net +1,771,715 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Geode Capital Management, LLC | 0.00% | Add +1503.9% | 1,192,925 | $716K |
| Vanguard Capital Management LLC | 0.00% | — | 708,168 | $425K |
| State Street Corp. | 0.00% | Add +5053.0% | 607,897 | $365K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 585,198 | $351K |
| BlackRock, Inc. | 0.00% | No change | 259,946 | $156K |
| Northern Trust Corp. | 0.00% | Add +2285.8% | 243,943 | $146K |
| Two Sigma Investments, LP | 0.00% | Reduce -6.0% | 37,427 | $22K |
| UBS Group AG | 0.00% | Add +1394.6% | 32,417 | $19K |
| Vanguard Global Advisers, LLC | 0.00% | — | 32,201 | $19K |
| Mason & Associates Inc | 0.00% | No change | 10,000 | $6K |
| Morgan Stanley | 0.00% | Add +0.1% | 9,274 | $6K |
| Global Trust Asset Management, LLC | 0.00% | New | 1,818 | $1K |
| Citigroup Inc. | 0.00% | Add +35200.0% | 353 | $212 |
| FMR LLC | 0.00% | New | 290 | $174 |
| Wells Fargo & Company | 0.00% | No change | 224 | $134 |
| NFSG Corp | 0.00% | No change | 86 | $52 |
| Cwm, LLC | 0.00% | No change | 28 | $17 |
| Burk Holdings LLC | 0.00% | New | 27 | $16 |
| Danske Bank A/S | 0.00% | No change | 3 | $2 |
| Royal Bank of Canada | 0.00% | No change | 32 | $0 |
"% of holder's portfolio" is IBO's weight in each manager's 13F, not the share of Impact Biomedical Inc. the manager owns.